Purdue Pharma, the maker of OxyContin, announced late Sunday that it has filed for Chapter 11 bankruptcy protection, as part of a proposed settlement that would see the company closed and much of its value invested into settling the myriad lawsuits at the state and local levels across the nation that have been filed against it.
While Purdue Pharma is one of the defendants in the I-75 Corridor opioid lawsuit filed by district attorneys general in East Tennessee, including 8th Judicial District Attorney General Jared Effler, Effler said Monday that the lawsuit would not be deterred.
“While the agreement — if approved by the bankruptcy court — settles claims made by my office, and on behalf of cities and counties against Purdue, it does not satisfy our complaints against the remaining defendants,” Effler said. “More than one pharmaceutical company helped create this crisis. Mallinckrodt, Endo and Teva played significant roles in the overprescription and diversion of opioids in our region, and Purdue’s actions will not alter our focus on holding them accountable, whether in circuit court or bankruptcy proceedings.”
The I-75 Corridor lawsuit is one of three filed in Tennessee by district attorneys general against pharmaceutical manufacturers and others. In all, 14 district attorneys, representing 47 counties, have joined forces to challenge pharmaceutical manufacturers and distributors for their roles in the opioid epidemic.